Toggle light / dark theme

Tirzepatide moves more than half of treated teens below obesity threshold, new clinical trial reports

Tirzepatide (Zepbound) is a once-weekly injectable medication that hits two targets at once. This dual-action drug mimics the effects of two natural gut hormones in the body—glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). Working together, these hormones keep blood sugar in check, slow the movement of food through the gut and signal the brain about fullness, which helps manage appetite and food intake.

A Phase III clinical trial called SURMOUNT-ADOLESCENTS tested whether a once-weekly dose of tirzepatide combined with healthy lifestyle counseling is safe and effective for helping teenagers lose weight and improve their health.

A total of 160 teenagers across 31 medical centers in six countries who had obesity or were overweight with at least one related health complication such as high blood pressure or prediabetes received either a once-weekly shot of tirzepatide or a placebo for 72 weeks.

Leave a Comment

Lifeboat Foundation respects your privacy! Your email address will not be published.